KERENDIA’s payer coverage is stronger than ever, with ~270 million lives covered1
Patients who need help paying for their KERENDIA prescription should call 1-888-KERENDIA (537-3634) or visit www.KERENDIASavings.com to learn more about the affordability solutions offered by Bayer.
There are 2 savings offers available to help your eligible patients start and stay on KERENDIA:
*Patients are eligible if they are commercially insured and may pay as little as $0 and save up to $3000 per year. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. Full terms and conditions apply, see www.KERENDIAsavings.com
†Terms and conditions apply. Call 1-888-KERENDIA (537-3634) or visit www.KERENDIAsavings.com for more information.
Access Services by Bayer™ is working with CoverMyMeds®‡ to provide the support your patients count on, with enhanced services you can trust from CoverMyMeds®.
Access a full suite of resources available for your practice to help get your patients access to KERENDIA:
- Prior Authorization and Appeals support
- Access to pharmacy-initiated Prior Authorization requests
- Payer experts available by phone or through chat to address questions
- Weekly live demos of the CoverMyMeds® platform
‡CoverMyMeds® is an independent party.
PA=prior authorization.
You may also contact Access Services by Bayer for support at 1-800-288-8374
Here are additional resources you may find helpful to gain patient access to KERENDIA:
Do you have a patient who needs additional assistance?
The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Please have your patient contact the program at 1-866-2BUSPAF (228-7723) Monday–Friday, 9:00 AM–6:00 PM EST, or visit the foundation website at www.patientassistance.bayer.us to see if they might qualify for assistance.
INDICATION:
KERENDIA is indicated to reduce the
risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS:
- Concomitant use with strong CYP3A4 inhibitors
- Patients with adrenal insufficiency
WARNINGS AND PRECAUTIONS:
- Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
MOST COMMON ADVERSE REACTIONS:
- From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3.9%), and hyponatremia (1.3% vs 0.7%)
DRUG INTERACTIONS:
- Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
- Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
- Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers
USE IN SPECIFIC POPULATIONS:
- Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
- Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)
Please read the Prescribing Information for KERENDIA.
Reference: 1. Data on file. Bayer.
